Insulin glulisine

also known as Apidra · glulisine · HMR1964 · glulisine insulin · Apidra (insulin glulisine) · insulin, glulisine, Apidra · Insuline glulisine

Protein / enzyme biologic

Developed for: type 2 diabetes mellitus · type 1 diabetes mellitus · hyperglycemia · diabetes mellitus · Alzheimer disease · chronic obstructive pulmonary disease · cognitive impairment with or without cerebellar ataxia · diabetic ketoacidosis
+5 more
· Down syndrome · localized lipodystrophy · myocardial infarction · gestational diabetes · glucose metabolism disease
Investigated by: Sanofi · Emory University · HealthPartners Institute · IKFE Institute for Clinical Research and Development · Medical University of Warsaw · Centre Hospitalier Universitaire Dijon
+26 more
· ikfe-CRO GmbH · Ajou University · East West Neo Medical Center · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Guillermo Umpierrez, MD · Halozyme Therapeutics · Hanyang University · Hospital Universitario Central de Asturias · India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals · Inha University Hospital · Jeju National University Hospital · Kinderkrankenhaus auf der Bult · Korea University Guro Hospital · Kyunghee University Medical Center · Medical University of South Carolina · National Cancer Institute (NCI) · Novo Nordisk A/S · Ohio University · Pontificia Universidad Catolica de Chile · Population Health Research Institute · Texas A&M University · The Catholic University of Korea · The Royal Bournemouth Hospital · Universidad Nacional de Asunción · University of Medicine and Dentistry of New Jersey · Western University of Health Sciences

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (2)	US (FDA)	APIDRA SOLOSTAR	—	2007-04-12 – 2008-10-24	fda.gov ↗
Approved	EU (EMA)	Apidra	—	2004-09-27	europa.eu ↗
Approved	US (FDA)	APIDRA SOLOSTAR	—	2004-04-16	fda.gov ↗

Trials 67 · started per year

today

US approved 2004

EU approved 2004

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 19 trials
Phase 1	NCT02432716	Apr 2015 → Oct 2018	Down syndrome	HealthPartners Institute	Completed	No outcome recorded
Phase 1	NCT00979875	Sep 2009 → Feb 2010	—	Halozyme Therapeutics	Completed	No outcome recorded
Phase 1	NCT01159353	Sep 2007 → Apr 2008	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 1	NCT00824668	Aug → Oct 2007	type 2 diabetes mellitus	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT00310297	Nov → Dec 2004	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 1	NCT00311077	Apr → Oct 2004	diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 1	NCT00297583	Apr → May 2004	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 1	NCT00368394	Jan 2004 → ?	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 1	NCT00290043	Dec 2001 → Mar 2002	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT02503501	Sep 2015 → Feb 2019	Alzheimer disease, cognitive impairment with or without cerebellar ataxia	HealthPartners Institute	Terminated	No outcome recorded
Phase 2	NCT01436045	Sep 2011 → Jun 2013	Alzheimer disease	HealthPartners Institute	Completed	No outcome recorded
Phase 319 trials
Phase 3	NCT00943709	May 2009 → Mar 2010	hyperglycemia, leukemia	University of Medicine and Dentistry of New Jersey	Withdrawn	No outcome recorded
Phase 3	NCT00640991	Apr 2008 → Jun 2010	hyperglycemia, myocardial infarction	Population Health Research Institute	Completed	No outcome recorded
Phase 3	NCT00467376	Jan 2007 → Jun 2008	diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00562133	Dec 2006 → Mar 2007	type 2 diabetes mellitus	IKFE Institute for Clinical Research and Development	Completed	No outcome recorded
Phase 3	NCT00272064	Oct 2005 → May 2008	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00135941	Aug 2005 → Sep 2007	diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00115570	Apr 2005 → Nov 2006	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00397553	Jan 2005 → Dec 2007	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00174642	Dec 2004 → Dec 2008	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00290979	Dec 2004 → ?	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00174668	Nov 2004 → Nov 2007	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00546702	Sep 2004 → Feb 2005	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00545337	Sep 2004 → Jun 2005	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00135083	Aug 2004 → Nov 2007	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00135096	Aug 2004 → Jul 2007	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00272012	Jul 2004 → Sep 2006	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00135057	Apr 2004 → Aug 2005	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00290927	Dec 2003 → ?	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT00046150	May → Dec 2002	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded

Phase 435 trials
Phase 4	NCT04019821	Jan 2020 → Jan 2023	type 1 diabetes mellitus	Medical University of Warsaw	Completed	No outcome recorded
Phase 4	NCT04157738	Nov 2019 → Dec 2020	type 1 diabetes mellitus	Emory University	Completed	No outcome recorded
Phase 4	NCT03328845	Jan 2017 → Nov 2020	type 1 diabetes mellitus	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	Completed	No outcome recorded
Phase 4	NCT02987751	Dec 2016 → Sep 2018	type 2 diabetes mellitus	India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals	Completed	No outcome recorded
Phase 4	NCT02914886	Sep 2016 → Apr 2019	localized lipodystrophy, type 1 diabetes mellitus	Kinderkrankenhaus auf der Bult	Completed	No outcome recorded
Phase 4	NCT02276859	Oct 2014 → Sep 2015	type 1 diabetes mellitus	Medical University of Warsaw	Completed	No outcome recorded
Phase 4	NCT02333851	Jun 2013 → Feb 2014	type 2 diabetes mellitus	Hospital Universitario Central de Asturias	Terminated	No outcome recorded
Phase 4	NCT01234597	Dec 2012 → Apr 2015	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT02048189	Mar 2012 → Feb 2015	—	Centre Hospitalier Universitaire Dijon	Terminated	No outcome recorded
Phase 4	NCT01889914	Jan 2012 → Mar 2015	type 2 diabetes mellitus	Centre Hospitalier Universitaire Dijon	Unknown	No outcome recorded
Phase 4	NCT01500850	Oct 2011 → Oct 2012	type 2 diabetes mellitus	ikfe-CRO GmbH	Unknown	No outcome recorded
Phase 4	NCT01417897	Sep 2011 → May 2012	type 2 diabetes mellitus	ikfe-CRO GmbH	Unknown	No outcome recorded
Phase 4	NCT01678235	Sep 2011 → Sep 2012	type 1 diabetes mellitus	Medical University of Warsaw	Completed	No outcome recorded
Phase 4	NCT01202474	May 2011 → Oct 2012	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT01203111	Dec 2010 → Jul 2012	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT01204593	Nov 2010 → Jan 2013	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT01212913	Aug 2010 → May 2012	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT01087567	Jul 2010 → Jan 2014	type 2 diabetes mellitus	Ohio University	Completed	No outcome recorded
Phase 4	NCT01122979	Jul 2010 → Oct 2013	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT01081938	Feb 2010 → Feb 2011	type 2 diabetes mellitus	Sanofi	Terminated	No outcome recorded
Phase 4	NCT01079364	Jan 2010 → Jul 2012	type 2 diabetes mellitus	Sanofi	Terminated	No outcome recorded
Phase 4	NCT00979628	Jan 2010 → Mar 2012	hyperglycemia, type 2 diabetes mellitus	Guillermo Umpierrez, MD	Completed	No outcome recorded
Phase 4	NCT01013571	Oct 2009 → Jan 2012	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT00964574	Jul 2009 → Jul 2010	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT00965549	Jul 2009 → Dec 2012	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT02278913	Apr 2009 → Apr 2010	diabetes mellitus, hyperglycemia	Universidad Nacional de Asunción	Completed	No outcome recorded
Phase 4	NCT00607087	Jan 2008 → Jun 2009	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT00596687	Dec 2007 → Dec 2009	hyperglycemia, type 2 diabetes mellitus	Emory University	Completed	No outcome recorded
Phase 4	NCT00590044	Dec 2007 → Jun 2008	diabetic ketoacidosis	Emory University	Completed	No outcome recorded
Phase 4	NCT00526513	Jul 2007 → May 2008	diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT00539448	Apr 2007 → Dec 2008	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT00474838	Apr 2007 → Aug 2012	type 2 diabetes mellitus	Kyunghee University Medical Center	Completed	No outcome recorded
Phase 4	NCT00360698	Jul 2006 → Aug 2008	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT00384085	May 2006 → Mar 2010	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT00489190	Aug 2005 → ?	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded

Phase not applicable2 trials
—	NCT01974544	May 2013 → Dec 2015	type 2 diabetes mellitus	Pontificia Universidad Catolica de Chile	Unknown	No outcome recorded
—	NCT00467636	Jul 2007 → May 2009	chronic obstructive pulmonary disease, hyperglycemia	The Royal Bournemouth Hospital	Terminated	No outcome recorded

Also used as a comparator or background therapy in 41 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT00969592 Comparator	Nov → Dec 2007	diabetes mellitus	Profil Institute for Metabolic Research GmbH	Completed	No outcome recorded
Phase 29 trials
Phase 2	NCT02846831 Comparator	Jan 2019 → Jan 2020	type 1 diabetes mellitus	Montreal Clinical Research Institute	Completed	No outcome recorded
Phase 2	NCT02488616 Comparator	Mar → Nov 2018	type 1 diabetes mellitus	Montreal Clinical Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT02490098 Comparator	Jan → Jul 2018	type 1 diabetes mellitus	Montreal Clinical Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT02798250 Comparator	Jun 2016 → Mar 2017	type 1 diabetes mellitus	Montreal Clinical Research Institute	Completed	No outcome recorded
Phase 2	NCT02626936 Comparator	Jan → Jun 2016	type 1 diabetes mellitus	Montreal Clinical Research Institute	Completed	No outcome recorded
Phase 2	NCT01662921 Comparator	Apr 2013 → Jan 2015	gestational diabetes	Sansum Diabetes Research Institute	Completed	No outcome recorded
Phase 2	NCT01194258 Background	Aug 2010 → Aug 2011	type 2 diabetes mellitus	Halozyme Therapeutics	Completed	No outcome recorded
Phase 2	NCT01194245 Background	Aug 2010 → Aug 2011	type 1 diabetes mellitus	Halozyme Therapeutics	Completed	No outcome recorded
Phase 2	NCT02846857 Comparator	? → Jul 2019	type 1 diabetes mellitus	Montreal Clinical Research Institute	Withdrawn	No outcome recorded

Phase 37 trials
Phase 3	NCT07070752 Comparator	Apr → Nov 2023	type 1 diabetes mellitus	Geropharm	Completed	No outcome recorded
Phase 3	NCT04974528 Comparator	Sep 2021 → Oct 2024	type 1 diabetes mellitus, type 2 diabetes mellitus	Mannkind Corporation	Completed	No outcome recorded
Phase 3	NCT03529123 Background	Jun 2018 → Nov 2019	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT01768559 Comparator	Jan 2013 → Dec 2014	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 3	NCT01792830 Comparator	Oct 2012 → Feb 2014	glucose metabolism disease	Emory University	Completed	No outcome recorded
Phase 3	NCT00670228 Comparator	Apr 2008 → Nov 2009	—	Sanofi	Terminated	No outcome recorded
Phase 3	NCT00271284 Background	Oct 2005 → Sep 2008	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded

Phase 419 trials
Phase 4	NCT04196231 Comparator	Nov 2019 → Sep 2020	type 2 diabetes mellitus	University of Campania Luigi Vanvitelli	Completed	No outcome recorded
Phase 4	NCT04124302 Background	Oct 2019 → Mar 2024	type 1 diabetes mellitus	Medical University of Warsaw	Completed	No outcome recorded
Phase 4	NCT03359837 Background	Jan 2018 → Jun 2020	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT03260868 Background	Sep 2017 → Nov 2018	type 1 diabetes mellitus	Sanofi	Terminated	No outcome recorded
Phase 4	NCT03013985 Background	May 2017 → Mar 2019	type 2 diabetes mellitus	Emory University	Completed	No outcome recorded
Phase 4	NCT02688933 Background	May 2016 → Jun 2017	type 1 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT02685449 Comparator	Feb 2016 → Feb 2018	type 1 diabetes mellitus	Medical University of Warsaw	Unknown	No outcome recorded
Phase 4	NCT03112538 Comparator	Jan 2016 → Dec 2018	type 2 diabetes mellitus	Clinical Research Centre, Malaysia	Unknown	No outcome recorded
Phase 4	NCT02276196 Comparator	Sep 2014 → Apr 2016	diabetes mellitus, diabetic kidney disease	Amsterdam UMC, location VUmc	Completed	No outcome recorded
Phase 4	NCT01848990 Background	Mar 2013 → Feb 2014	type 1 diabetes mellitus	Halozyme Therapeutics	Completed	No outcome recorded
Phase 4	NCT01524705 Comparator	Aug 2012 → Jul 2014	type 2 diabetes mellitus	University of Washington	Completed	No outcome recorded
Phase 4	NCT01594060 Comparator	Jun 2012 → Oct 2014	type 2 diabetes mellitus	HaEmek Medical Center, Israel	Completed	No outcome recorded
Phase 4	NCT01131052 Comparator	Mar 2011 → Dec 2013	hyperglycemia, type 2 diabetes mellitus	Guillermo Umpierrez	Completed	No outcome recorded
Phase 4	NCT01143948 Comparator	Jan → Apr 2011	cirrhosis of liver, type 2 diabetes mellitus	Cairo University	Unknown	No outcome recorded
Phase 4	NCT01121835 Background	Feb 2010 → Mar 2012	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 4	NCT00913497 Comparator	Jun 2009 → Jan 2012	type 1 diabetes mellitus	Corewell Health West	Completed	No outcome recorded
Phase 4	NCT00467649 Comparator	May 2007 → Apr 2008	type 2 diabetes mellitus	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00283049 Background	Feb 2006 → Nov 2008	type 2 diabetes mellitus	Sanofi	Terminated	No outcome recorded
Phase 4	NCT00394407 Comparator	Sep 2005 → Jun 2006	hyperglycemia, type 2 diabetes mellitus	Emory University	Completed	No outcome recorded

Phase not applicable5 trials
—	NCT04965051 Comparator	Aug 2021 → Dec 2023	type 1 diabetes mellitus	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
—	NCT01621776 Comparator	Jun 2011 → Aug 2012	type 1 diabetes mellitus	University of Florida	Completed	No outcome recorded
—	NCT01855243 Comparator	Mar 2010 → Feb 2014	type 2 diabetes mellitus	Cairo University	Completed	No outcome recorded
—	NCT00528918 Comparator	Jun 2007 → May 2011	type 2 diabetes mellitus	Carl T. Hayden VA Medical Center	Completed	No outcome recorded
—	NCT00927524 Comparator	Apr 2005 → Apr 2006	type 1 diabetes mellitus	Vanderbilt University	Completed	No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 110 sources stand behind the page.

Field	Value	Cited text
Known as	Insulin Glulisine	“Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes...” NCT00546702 ↗ 77 “Beginning 24 hours after maintenance of oral or enteral feedings patients receive an intensive regimen of insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4...” NCT00943709 ↗ “Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart)” NCT03112538 ↗ “Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening.” NCT02688933 ↗ “Individualized dose of RAA injection (insulin aspart, insulin lispro or insulin glulisine) for each patient for 26 weeks.” NCT04974528 ↗ “supporting its use as a biosimilar insulin glulisine” PMID 41366610 ↗ Dec 2025 “Insulin Glulisine (HMR1964) Injected Subcutaneously” NCT00545337 ↗ “insulin glargine insulin glulisine” NCT00474838 ↗ “Apidra (insulin glulisine)” NCT00979628 ↗ NCT00397553 ↗ NCT01194258 ↗ NCT00174642 ↗ NCT00135096 ↗ NCT02276859 ↗ NCT01203111 ↗ NCT01131052 ↗ NCT02276196 ↗ NCT00539448 ↗ NCT01500850 ↗ NCT00310297 ↗ NCT00283049 ↗ NCT00969592 ↗ NCT00965549 ↗ NCT00272064 ↗ NCT02503501 ↗ NCT01081938 ↗ NCT02685449 ↗ NCT01212913 ↗ NCT04124302 ↗ NCT00174668 ↗ NCT00135057 ↗ NCT01121835 ↗ NCT00360698 ↗ NCT04019821 ↗ NCT00489190 ↗ NCT01768559 ↗ NCT01594060 ↗ NCT01122979 ↗ NCT00913497 ↗ NCT01234597 ↗ NCT01678235 ↗ NCT00670228 ↗ NCT00927524 ↗ NCT03359837 ↗ NCT01662921 ↗ NCT01159353 ↗ NCT01204593 ↗ NCT00046150 ↗ NCT01079364 ↗ NCT00290043 ↗ NCT00526513 ↗ NCT00115570 ↗ NCT00272012 ↗ NCT00290927 ↗ NCT00135083 ↗ NCT01194245 ↗ NCT00979875 ↗ NCT00964574 ↗ NCT00135941 ↗ NCT01417897 ↗ NCT01848990 ↗ NCT00368394 ↗ NCT00384085 ↗ NCT00271284 ↗ NCT00824668 ↗ NCT00596687 ↗ NCT00467649 ↗ NCT00297583 ↗ NCT00311077 ↗ NCT01436045 ↗ NCT00467376 ↗ NCT00290979 ↗ NCT00467636 ↗ NCT00607087 ↗ NCT00562133 ↗ NCT01013571 ↗ NCT01202474 ↗ NCT03529123 ↗
Known as	Apidra	“This study will compare how well regular insulin will compare to glargine (Lantus®) once daily plus glulisine (Apidra®) insulin before meals in hospitalized patients with type...” NCT00394407 ↗ 24 “Beginning 24 hours after maintenance of oral or enteral feedings patients receive an intensive regimen of insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4...” NCT00943709 ↗ “Pharmacodynamic and Pharmacokinetic Properties of Insulin Glulisine (Apidra) in Comparison to Insulin Lispro (Humalog) in Healthy Lean and Obese Subjects” NCT00311077 ↗ “pre-meal insulin glulisine (Apidra) versus post-meal Apidra, in patients receiving insulin glargine (Lantus) as basal insulin.” NCT00135096 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).” NCT02798250 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02490098 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02626936 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846857 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846831 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02488616 ↗ “rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])” NCT00467649 ↗ “Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner” NCT02333851 ↗ “the patient receive continuous rapid insulin (APIDRA ®)with an external pump.” NCT01889914 ↗ “Levemir/Lantus/Tresiba plus NovoLog/Humalog/Apidra” NCT04965051 ↗ “glargine (Lantus) + glulisine (Apidra)” NCT00590044 ↗ “Drug: Apidra (insulin glulisine)” NCT01013571 ↗ “Insulin Glulisine (Apidra)” NCT00670228 ↗ “Apidra glulisine (HMR1964)” NCT00489190 ↗ “Glulisine (Apidra)” NCT00528918 ↗ “(Apidra®)” NCT00913497 ↗ NCT02048189 ↗ NCT03328845 ↗ NCT02914886 ↗ NCT01621776 ↗ NCT03260868 ↗
Known as	Apidra (insulin glulisine)	“Apidra (insulin glulisine)” NCT00979628 ↗
Known as	glulisine	“Patients were randomized to receive a premixed human insulin formulation with 70% intermediate insulin plus 30% regular insulin (Mixtard 30®, Novo Nordisk) or a basal-bolus...” NCT02333851 ↗ 22 “The rapid-acting insulin analogue insulin glulisine (glulisine) was compared with insulin lispro (lispro) for efficacy and safety in Japanese patients with type 1 diabetes...” PMID 19614947 ↗ Jul 2009 “The short acting insulin analogue (lispro, aspart or glulisine) will be started at the dosage of 4 units before meals (3 times per day)” NCT04196231 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).” NCT02798250 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846857 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02488616 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02490098 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02626936 ↗ “Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)” NCT02846831 ↗ “A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.” NCT01087567 ↗ “To evaluate the safety and efficacy of insulin glulisine (glulisine) with and without oral antidiabetic drugs” PMID 19614946 ↗ Jul 2009 “Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved.” NCT01974544 ↗ “Prandial Insulins (aspart, glulisine or lispro).” NCT01524705 ↗ “Lispro, Aspart, glulisine” NCT04157738 ↗ NCT02987751 ↗ NCT01855243 ↗ NCT02278913 ↗ NCT01143948 ↗ NCT00590044 ↗ NCT00394407 ↗ NCT00528918 ↗ NCT02432716 ↗ NCT01792830 ↗
Known as	glulisine insulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00640991 ↗ 1 NCT03013985 ↗
Known as	HMR1964	“Evaluation of Efficacy and Safety of HMR1964 (Insulin Glulisine) in Subjects With Type 1 Diabetes Mellitus; Insulin Lispro Controlled, Open, Randomized, Parallel Group,...” NCT00290979 ↗ 8 “Dose-Exposure-Response Relationship of Insulin Glulisine (HMR1964) in Subjects With Type 1 Diabetes Mellitus Assessed With the Euglycemic Clamp Technique Using the Biostator (TM)” NCT00368394 ↗ “insulin glulisine (HMR 1964)” NCT00545337 ↗ “insulin glulisine (HMR 1964)” NCT00546702 ↗ “Insulin Glulisine (HMR1964)” NCT03529123 ↗ “Insulin glulisine (HMR1964)” NCT00046150 ↗ “INSULIN GLULISINE (HMR1964)” NCT00964574 ↗ “INSULIN GLULISINE (HMR1964)” NCT01234597 ↗ “Apidra glulisine (HMR1964)” NCT00489190 ↗
Known as	insulin, glulisine, Apidra	“insulin, glulisine, Apidra” NCT02432716 ↗
Known as	Insuline glulisine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00545337 ↗
Modality	Protein / enzyme biologic	“The rapid-acting insulin analogue insulin glulisine” PMID 19614947 ↗ Jul 2009
Route	Subcutaneous	“Continuous Subcutaneous Insulin Infusion (CSII)” NCT00046150 ↗